Delay of dimethylbenz[a]anthracene‐induced mammary tumorigenesis in transgenic mice by apoptosis induced by an unusual mutant p53 protein

Molecular Carcinogenesis

Volumn 14, Issue 2, 1995, Pages 75-83

  Li, Baolin ^a   Kittrell, Frances S ^a   Medina, Daniel ^a   Rosen, Jeffrey M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

7,12 dimethylbenz a anthracene; Apoptosis; breast cancer; p53

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; MUTANT PROTEIN; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMAL; APOPTOSIS; DNA REPLICATION; FEMALE; GENES, P53; MAMMAE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PREGNANCY; PROMOTER REGIONS (GENETICS); PROTEIN P53; RATS; SUPPORT, U.S. GOV'T, P.H.S.; TRANS-ACTIVATION (GENETICS);

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0028850656     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.2940140203     Document Type: Article

References (31)

1. Wild‐type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin‐6
2. p53–dependent apoptosis modulates the cytotoxicity of anticancer agents
3. p53 is required for radiation induced apoptosis in mouse thymocytes
4. Wild‐type p53 mediates apoptosis by E1A, which is inhibited by E1B
5. p53–dependent apoptosis suppresses tumor growth and progression in vivo
6. Apoptosis in cancer therapy
7. p53 status and efficacy of cancer therapy in vivo
8. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
9. Tumor spectrum analysis in p53–deficient mice
10. Spontaneous and carcinogen‐induced tumorigenesis in p53–deficient mice
11. p53–deficient mice are extremely susceptible to radiation‐induced, tumorigenesis
12. p53, guardian of Rb
13. p53 mutations occur infrequently in 7,12–dimethylbenzo[a]anthracene‐induced mammary tumors in BALB/c and p53 hemizygous mice
14. Arg‐Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development
15. Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation
16. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
17. Transforming growth factors β1, β2, and β3 messenger RNA and protein expression in mouse uterus and vagina during estrogen‐induced growth: A comparison to other estrogen‐regulated genes
18. Mammary tumorigenesis in chemical carcinogentreated mice: I. Incidence in BALB/c and C57BL mice
19. WAF1, a potential mediator of p53 tumor suppression
20. The p21 Cdk‐interacting protein Cip 1 is a potent inhibitor of G1 cyclin‐dependent kinases
21. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors
22. Incidence of c‐Ki‐ras activation in N‐methyl‐N‐nitrosourea‐induced mammary carcinomas in pituitary‐isografted mice
23. Prostate cancer in a transgenic mouse
24. The rat probasin gene promoter directs hormonally‐ and developmentally‐regulated expression of a heterologous gene specifically to the prostate in transgenic mice
25. Gain of function mutations in p53
26. Analysis of p53 mutations for transcriptional activity
27. Crystal structure of a p53 tumor suppressor‐DNA complex: Understanding tumorigenic mutations
28. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation
29. The p53 tumour suppressor gene
30. p53 mutations in breast cancer
31. Growth suppression of human head and neck cancer cells by the introduction of a wild‐type p54 gene via recombinant adenovirus